219 related articles for article (PubMed ID: 15678803)
1. [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
Henao HH; Osorio Y; Saravia NG; Gómez A; Travi B
Biomedica; 2004 Dec; 24(4):393-402. PubMed ID: 15678803
[TBL] [Abstract][Full Text] [Related]
2. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
[TBL] [Abstract][Full Text] [Related]
3. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
Brito NC; Rabello A; Cota GF
PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
Robledo SM; Valencia AZ; Saravia NG
J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
7. The effects of induced diabetes and cutaneous Leishmania infection on the pharmacokinetics of antimony in hamsters.
Radwan MA; Al Jaser MH; Al Rayes ZR
Ann Trop Med Parasitol; 2007 Mar; 101(2):133-42. PubMed ID: 17316499
[TBL] [Abstract][Full Text] [Related]
8. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
Yesilova Y; Surucu HA; Ardic N; Aksoy M; Yesilova A; Oghumu S; Satoskar AR
J Dermatolog Treat; 2016; 27(1):83-7. PubMed ID: 26105204
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
10. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
11. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
Hanson WL; Chapman WL; Waits VB; Lovelace JK
J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone and itraconazole improve the activity of pentavalent antimonial in the treatment of experimental cutaneous leishmaniasis.
Anversa L; Salles Tiburcio MG; Batista LR; Cuba MB; Nogueira Nascentes GA; Martins TY; Richini Pereira VB; Ruiz LDS; Dias da Silva VJ; Ramirez LE
Int J Antimicrob Agents; 2017 Aug; 50(2):159-165. PubMed ID: 28668672
[TBL] [Abstract][Full Text] [Related]
13. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
Soto J; Toledo J; Vega J; Berman J
Am J Trop Med Hyg; 2005 Apr; 72(4):421-2. PubMed ID: 15827279
[TBL] [Abstract][Full Text] [Related]
14. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M
Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis].
Sáenz RE; Paz HM; Johnson CM; Narvaez E; de Vásquez AM
Rev Med Panama; 1987 Sep; 12(3):148-57. PubMed ID: 2827242
[No Abstract] [Full Text] [Related]
17. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Grogl M; Thomason TN; Franke ED
Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
[TBL] [Abstract][Full Text] [Related]
18. Antimonial treatment of hamsters infected with Leishmania (Viannia) panamensis: assessment of parasitological cure with different therapeutic schedules.
Travi BL; Martinez JE; Zea A
Trans R Soc Trop Med Hyg; 1993; 87(5):567-9. PubMed ID: 8266413
[TBL] [Abstract][Full Text] [Related]
19. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.
Jackson JE; Tally JD; Ellis WY; Mebrahtu YB; Lawyer PG; Were JB; Reed SG; Panisko DM; Limmer BL
Am J Trop Med Hyg; 1990 Nov; 43(5):464-80. PubMed ID: 2173431
[TBL] [Abstract][Full Text] [Related]
20. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
